Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-01-31FDA Approved: LENALIDOMIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic lenalidomide (LENALIDOMIDE) under an Original Application (ANDA 216213).
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 trial evaluating SD-101 (TLR9 agonist) and BMS-986178 (anti-OX40 antibody) with radiation therapy for low-grade B-cell non-Hodgkin l…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Clinical trial registry update for a Chinese patient study on Marginal Zone Lymphoma. The study is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma [Phase 3]
A Phase 3 trial evaluating MIL62 in combination with Lenalidomide versus Lenalidomide alone for rituximab-refractory follicular lymphoma is …
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating MIL62 plus lenalidomide for relapsed/refractory indolent non-Hodgkin's lymphoma (follicular lymphom…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating SD-101 (TLR9 agonist) combined with Ibrutinib and radiation therapy in relapsed or refractory follicular lympho…
-
CLINICAL_TRIALS trial_result · 2024-09-24Clinical Trial Update: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib with rituximab and lenalidomide in previously untreated stage II-IV follicular lymphom…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation [Phase 2]
Phase 2 trial evaluating Zydelig (idelalisib) as maintenance therapy after autologous stem cell transplantation in B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL) [Phase 1, Phase 2]
A frontline combination of linperlisib and obinutuzumab is being studied in a Phase 1/2 trial for marginal zone lymphoma and is currently re…
-
FDA approval · 2024-09-11FDA Approved: LENALIDOMIDE — Original Application (Novugen Pharma (USA) LLC)
FDA approved the original application for lenalidomide from Novugen Pharma (USA) LLC, enabling a generic version of the cancer drug lenalido…
-
CLINICAL_TRIALS trial_result · 2024-09-04Clinical Trial Update: A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating the effect of Vitamin D on progression-free survival in indolent non-Hodgkin lymphoma has completed with results po…
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma [NA]
Clinical trial update for indolent localized GI lymphomas using 20 Gy involved-site radiotherapy (ISRT); currently recruiting for gastric or…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab [Phase 3]
A Phase 3 trial comparing Bendamustine plus Rituximab vs CHOP plus Rituximab in various non-Hodgkin lymphomas has completed.
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating first-line Orelabrutinib plus Obinutuzumab (O2) for Marginal Zone Lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas [Phase 3]
This Phase 3 trial update discusses how the duration of rituximab maintenance therapy may affect outcomes in various non-Hodgkin lymphomas, …
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy [NA]
Prospective clinical study evaluating orelabrutinib in combination with rituximab for primary marginal zone lymphoma that failed or was not …
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating Imvotamab monotherapy and in combination for relapsed/refractory non-Hodgkin lymphoma has been terminated…
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas [Phase 2]
A Phase 2 clinical trial evaluating a combination of orelabrutinib and obinutuzumab in previously untreated marginal zone lymphoma is curren…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. [Phase 2]
This Phase 2 trial is evaluating the first-line combination of orelabrutinib with obinutuzumab and lenalidomide (OGL regimen) for marginal z…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]
Phase Ib study of YY-20394 in participants with B-cell hematologic malignancies has completed, evaluating safety and preliminary activity ac…